{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Byetta&page=4",
    "query": {
      "intervention": "Byetta",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 185,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Byetta&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Byetta&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:55:00.035Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00679042",
      "title": "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Islets of Langerhans transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CellTrans Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2007-09-05",
      "completion_date": "2026-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679042"
    },
    {
      "nct_id": "NCT07932119",
      "title": "GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "GLP-1 Receptor Agonist Treatment"
      ],
      "interventions": [
        {
          "name": "GLP-1 Receptor Agonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25505,
      "start_date": "2025-01-01",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07932119"
    },
    {
      "nct_id": "NCT01144338",
      "title": "Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide Once Weekly",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 14752,
      "start_date": "2010-06-18",
      "completion_date": "2017-04-24",
      "has_results": true,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 139,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144338"
    },
    {
      "nct_id": "NCT01006889",
      "title": "Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-01",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006889"
    },
    {
      "nct_id": "NCT00518882",
      "title": "Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 467,
      "start_date": "2007-08",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-08",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518882"
    },
    {
      "nct_id": "NCT02981069",
      "title": "Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2017-12-15",
      "completion_date": "2023-03-19",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981069"
    },
    {
      "nct_id": "NCT06252623",
      "title": "Exenatide For Reducing the Reinforcing Effects of Cocaine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher D. Verrico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06252623"
    },
    {
      "nct_id": "NCT00508287",
      "title": "Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "BMS-686117",
          "type": "DRUG"
        },
        {
          "name": "Byetta",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2007-08",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2009-03-16",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508287"
    },
    {
      "nct_id": "NCT00650546",
      "title": "Role of Exenatide in NASH-a Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 8,
      "start_date": "2006-08",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Kansas City, Missouri • San Antonio, Texas",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00650546"
    },
    {
      "nct_id": "NCT00099320",
      "title": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 182,
      "start_date": "2004-05",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2015-02-23",
      "last_synced_at": "2026-11-19T07:55:00.035Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099320"
    }
  ]
}